Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer
Agendia Announces First Patient Enrolled in Prospective LESS Clinical Study, Sponsored by Unicancer, to De-escalate Endocrine Therapy in Women with Early Breast Cancer
IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a commercial-stage company focused on improving outcomes for breast cancer patients worldwide by providing physicians and patients with next-generation diagnostic and information solutions to inform optimized treatment decision-making, today announced it will present seven posters derived from the company’s FLEX Trial, the real-world, multicenter, prospective, observational breast cancer study at the American Society of Clinical Oncology Annual Meeting (ASCO) 2022.
IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide, today announced new data published in Genes, Chromosomes and Cancer (Genes) that show MammaPrint® and BluePrint® gene signatures represent and capture all of the original 10 hallmarks of cancer (HoCs), recognized as the biological capabilities acquired during the multi-step development of human cancer, as defined by Hanahan and Weinberg.
IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced that it is offering early access to its Digital MammaPrint platform for patients with breast cancer in Brazil, expanding the company’s offerings in the country with the goal of bringing essential information from cancer testing to the larger global breast cancer community. Brazil is the first country to have samples analyzed by Digital MammaPrint, allowing physicians and their patients to benefit from genomic insights derived from a digitized image of a breast cancer tumor. Results about individual tumors will now be informed by the new artificial intelligence (AI) platform, also providing better turnaround time for their treatment decisions.
IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced a multi-year partnership with Illumina, Inc. (NASDAQ: ILMN), to co-develop in vitro diagnostic (IVD) tests for oncology testing. The partnership is intended to advance the use of next-generation sequencing (NGS) for decentralized oncology testing and aligns with Illumina’s approach to IVD partnerships in oncology. Agendia joins Illumina’s growing portfolio of more than 30 IVD partners developing over 40 sequencing-based solutions for cancer prognosis, therapy selection, and other applications.
IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced the appointment of healthcare industry veterans Suja Chandrasekaran, MS and Scott Mendel, MBA to the Company’s Board of Directors.